Pantoloc (Pantoprazole)

Pantoprazole, the active ingredient in Pantoloc, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to manage gastro‑reflux disease and ulcers in adults. GNH USA supplies Pantoloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on conditions related to excess gastric acid secretion. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Erosive esophagitis: accelerates ulcer healing in the esophagus. - Peptic ulcer disease: supports ulcer closure and reduces recurrence risk.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: increased intestinal gas. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps or irregular heartbeat. - Fracture risk: reduced bone mineral density with long‑term use.

When prescribing Pantoloc, clinicians should consider several safety aspects. - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor for infections: prolonged acid suppression can increase risk of gastrointestinal infections. - Evaluate bone health: long‑term therapy may affect calcium absorption. - Review concomitant medications: potential for altered drug absorption. - Pregnancy and lactation: use only if clearly needed. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption. - Atazanavir: markedly decreased antiviral exposure. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR values. - Methotrexate: increased serum concentrations, especially in renal impairment. - Digoxin: modest increase in serum levels. - Iron supplements: decreased iron absorption when taken simultaneously.